The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review
- 494 Downloads
Inconsistent findings in the studies have been observed concerning the higher dose of statins use in the acute phase of ischemic stroke and transient ischemic attack (TIA). Therefore, we performed a systematic review to assess this issue. A computerized literature search in PubMed, Cochrane Library databases, and EMBASE for randomized controlled trials (RCTs) was conducted. The efficacy outcome indicators were National Institutes of Health Stroke Scale (NIHSS) score, infarct volume, and recurrence of stroke; the safety outcome indicators were intracranial hemorrhage events, cardiovascular and cerebrovascular events, and all-cause death. Pre-specified subgroup analyses were carried out. A total of seven RCTs with 1089 patients were included. Six studies reported the results of the NHISS score. A great reduction was found in NIHSS score in the statins group, and the difference is statistically significant [mean difference (MD) −1.15, 95% confidence interval (CI) −1.64 to −0.66, P < 0.00001]. However, no significant differences in the effect on recurrence of stroke [odds ratio (OR) 1.05, 95% CI 0.65–1.69, P = 0.85] (available in 3 studies), infarct volume [std. mean difference (SMD) 0.04, 95% CI −0.55 to 0.63, P = 0.89] (available in 2 studies), intracerebral hemorrhage events (OR 3.25, 95% CI 0.34–31.52, P = 0.31) (available in 2 studies), cardiovascular and cerebrovascular events (OR 0.70, 95% CI 0.35–1.43, P = 0.33) (available in 2 studies), and all-cause death (OR 1.18, 95% CI 0.60–2.35, P = 0.63) (available in 2 studies) were found. High-dose statin therapy in the acute phase of ischemic stroke and TIA significantly reduce the NIHSS score and improve short-term functional outcome without increasing related adverse events.
KeywordsHigh-dose statins Ischemic stroke TIA Acute phase Systematic review
Our study had no funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
All procedures in studies involving human participants are in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration. This article does not contain any studies with animals performed by any of the author.
For this type of study, informed consent is not required.
- 7.Tuttolomondo A, Di Raimondo D, Pecoraro R, Maida C, Arnao V, Della Corte V, Simonetta I, Corpora F, Di Bona D, Maugeri R, Iacopino DG, Pinto A (2016) Early high-dosage atorvastatin treatment improved serum immune-inflammatory markers and functional outcome in acute ischemic strokes classified as large artery atherosclerotic stroke: a randomized trial. Medicine 95:e3186CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Kostaki S, Papadopoulou M, Angelopoulou SM, Konstantara F, Savopoulos C, Hatzitolios AI (2015) Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke. Atherosclerosis 243:65–70CrossRefPubMedGoogle Scholar
- 12.Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 updated March 2011. The Cochrane Collaboration 2011. http://www.cochrane-handbook.org. Accessed 06 June 2016
- 18.Arboix A, García-Eroles L, Oliveres M, Targa C, Balcells M, Massons J (2010) Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? BMC Neurol 10:47CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Fernándezde Bobadilla J, Moreno R, Fernández C, Martínez A, Sánchez-Maestre C, Ezpeleta-Echevarri D (2009) Effect of intensive treatment with atorvastatin versus standard doses of statins on the risk of stroke. A meta-analysis from five randomized trials including 25,709 patients. Revue Neurol 48:561–565Google Scholar
- 27.Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757–767CrossRefPubMedGoogle Scholar
- 28.Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681Google Scholar
- 32.Fukuma K (2015) Early statin intervention can reduce the early neurological deterioration and recurrence in acute lacunar stroke. Stroke 46:TP65Google Scholar